{"id":16172,"date":"2023-07-13T21:02:00","date_gmt":"2023-07-13T13:02:00","guid":{"rendered":"https:\/\/flcube.com\/?p=16172"},"modified":"2024-12-01T21:08:00","modified_gmt":"2024-12-01T13:08:00","slug":"shanghai-circode-bio-and-pfizer-collaborate-to-explore-circular-rna-therapy-potential","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16172","title":{"rendered":"Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential"},"content":{"rendered":"\n

Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE<\/a>) to explore the therapeutic potential of circular RNA (circRNA). This strategic collaboration aims to fully leverage Circode Bio’s unique circular RNA technology platform and combine it with Pfizer’s extensive expertise and experience in the pharmaceutical industry. Both parties will collaborate to deepen their understanding of circular RNA technology and facilitate its development into drug candidate molecules.<\/p>\n\n\n\n

Understanding Circular RNA (circRNA) and Its Therapeutic Potential<\/strong>
Circular RNAs (circRNA) are covalently closed endogenous biomolecules with tissue-specific and cell-specific expression patterns in Eukaryotes. Their biogenesis is regulated by specific Cis-regulatory elements and Trans-acting factors. Initially discovered in 1976 and once considered by-products of incorrect mRNA splicing, circRNAs gained renewed attention in 2013 when two research papers published in Nature highlighted their regulatory effects. These studies indicated that circRNAs can act as miRNA sponges, regulating the expression of other genes. Since then, circRNAs have been recognized as important molecules in normal cell differentiation, tissue homeostasis, disease development, and immune metabolism. They are also characterized by high stability, being unaffected by RNA Exonuclease, and have been implicated in a variety of human diseases, including diabetes, nervous system diseases, and cardiovascular diseases.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE)…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1453,863,309,64],"class_list":["post-16172","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-circode-bio","tag-nyse-pfe","tag-pfizer","tag-rnai-aso"],"yoast_head":"\nShanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE) to explore the therapeutic potential of circular RNA (circRNA). This strategic collaboration aims to fully leverage Circode Bio's unique circular RNA technology platform and combine it with Pfizer's extensive expertise and experience in the pharmaceutical industry. Both parties will collaborate to deepen their understanding of circular RNA technology and facilitate its development into drug candidate molecules.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16172\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16172\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-13T13:02:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-01T13:08:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16172#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16172\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential\",\"datePublished\":\"2023-07-13T13:02:00+00:00\",\"dateModified\":\"2024-12-01T13:08:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16172\"},\"wordCount\":217,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Circode Bio\",\"NYSE: PFE\",\"Pfizer\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16172#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16172\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16172\",\"name\":\"Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-13T13:02:00+00:00\",\"dateModified\":\"2024-12-01T13:08:00+00:00\",\"description\":\"Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE) to explore the therapeutic potential of circular RNA (circRNA). This strategic collaboration aims to fully leverage Circode Bio's unique circular RNA technology platform and combine it with Pfizer's extensive expertise and experience in the pharmaceutical industry. Both parties will collaborate to deepen their understanding of circular RNA technology and facilitate its development into drug candidate molecules.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16172#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16172\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16172#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential - Insight, China's Pharmaceutical Industry","description":"Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE) to explore the therapeutic potential of circular RNA (circRNA). This strategic collaboration aims to fully leverage Circode Bio's unique circular RNA technology platform and combine it with Pfizer's extensive expertise and experience in the pharmaceutical industry. Both parties will collaborate to deepen their understanding of circular RNA technology and facilitate its development into drug candidate molecules.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16172","og_locale":"en_US","og_type":"article","og_title":"Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=16172","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-13T13:02:00+00:00","article_modified_time":"2024-12-01T13:08:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16172#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16172"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential","datePublished":"2023-07-13T13:02:00+00:00","dateModified":"2024-12-01T13:08:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16172"},"wordCount":217,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Circode Bio","NYSE: PFE","Pfizer","RNAi \/ ASO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16172#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16172","url":"https:\/\/flcube.com\/?p=16172","name":"Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-13T13:02:00+00:00","dateModified":"2024-12-01T13:08:00+00:00","description":"Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE) to explore the therapeutic potential of circular RNA (circRNA). This strategic collaboration aims to fully leverage Circode Bio's unique circular RNA technology platform and combine it with Pfizer's extensive expertise and experience in the pharmaceutical industry. Both parties will collaborate to deepen their understanding of circular RNA technology and facilitate its development into drug candidate molecules.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16172#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16172"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16172#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16172"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16172\/revisions"}],"predecessor-version":[{"id":16174,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16172\/revisions\/16174"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}